PD 123,319 di(trifluoroacetate) salt hydrate
SIGMA/P186 - powder, ≥98% (HPLC)
Synonym: S-
CAS Number: 136676-91-0
Empirical Formula (Hill Notation): C31H32N4O3 · 2C2HF3O2 · xH2O
Molecular Weight: 736.66 (anhydrous basis)
MDL Number: MFCD11046022
Linear Formula: C31H32N4O3 · 2C2HF3O2 · xH2O
Product Type: Chemical
| assay | ≥98% (HPLC) |
| form | powder |
| InChI | 1S/C31H32N4O3.2C2HF3O2.H2 |
| InChI key | PTSUEYBWHKDYBS-FPCIESGBSA |
| SMILES string | O.OC(=O)C(F)(F)F.OC(=O)C( |
| solubility | H2O: 10 mg/mL, clear |
| storage condition | desiccated |
| storage temp. | 2-8°C |
| Application: | PD123,319 di (trifluoroacetate) salt hydrate has been used in following experimental studies: • To determine the effect of Angiotensin II (Ang II) on alveolar fluid clearance (AFC). • To study the effect of PD123319 on AngII-induced abdominal aortic aneurysms (AAAs). • To study its effect on Ang II-induced LRP1 overexpression and function in vascular smooth muscle cells (VSMCs) culture. |
| Biochem/physiol Actions: | PD123,319 di (trifluoroacetate) salt hydrate is a widely used angiotensin II subtype-2 receptor (AT2R) antagonist to study the role of AT2 receptor in vitro and in vivo. It increases the AngII-induced abdominal aortic aneurysms (AAAs) without interacting with AT2 receptor. |
| Disclaimer: | Hygroscopic |
| Packaging: | 10 mg in poly bottle |
| Symbol | GHS07 |
| Signal word | Warning |
| Hazard statements | H315 - H319 - H335 |
| Precautionary statements | P302 + P352 - P305 + P351 + P338 |
| Hazard Codes | Xi |
| Risk Statements | 36/37/38 |
| Safety Statements | 26 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352202 |

